Table 1 Anticancer drug target genes are identified by total support ranking. In the table, C1, C2, and C3 denote NCBI gene symbols of the top three genes with the highest total support. The underlined and bold genes (42 out of 51) were previously reported as anticancer drug target genes (see Table S2), in which genes in bold are approved for drug manufacture whereas the remaining ones are clinical trial/potential. The remaining neither underlined nor bold genes in the top three highest-ranking genes that have not yet been fully investigated may be promising anticancer drug target genes.

From: Identification of anticancer drug target genes using an outside competitive dynamics model on cancer signaling networks